Asymptomatic Bacteriuria: Prevalence, Diagnosis, Management, and Current Antimicrobial Stewardship Implementations

医学 菌尿 无症状的 重症监护医学 泌尿系统 抗菌管理 内科学 儿科 抗生素 抗生素耐药性 生物 微生物学
作者
Tyler Luu,Fritzie S Albarillo
出处
期刊:The American Journal of Medicine [Elsevier]
卷期号:135 (8): e236-e244 被引量:38
标识
DOI:10.1016/j.amjmed.2022.03.015
摘要

Asymptomatic bacteriuria is a common clinical condition that often leads to unnecessary treatment. It has been shown that incidence of asymptomatic bacteriuria increases with age and are more prominent in women than men. In older women, the incidence of asymptomatic bacteriuria is recorded to be more than 15%. This number increased up to 50% for those who reside in long-term care facilities. In most scenarios, asymptomatic bacteriuria does not lead to urinary tract infections, and therefore, antibiotic treatment of asymptomatic bacteriuria has not been shown to improve patient outcomes. In 2019, the Infectious Disease Society of America (IDSA) updated its asymptomatic bacteriuria management guidelines, which emphasized on the risks and benefits of treating the condition. Women who are pregnant should be screened for asymptomatic bacteriuria in the first trimester and treated, if positive. Individuals who are undergoing endoscopic urologic procedures should be screened and treated appropriately for asymptomatic bacteriuria as well. Treating asymptomatic bacteriuria in individuals with diabetes, neutropenia, spinal cord injuries, indwelling urinary catheters, and so on has not been found to improve clinical outcomes. Furthermore, unnecessary treatment is often associated with unwanted consequences including but not limited to increased antimicrobial resistance, Clostridioides difficile infection, and increased health care cost. As a result, multiple antibiotic stewardship programs around the US have implemented protocols to appropriately reduce unnecessary treatment of asymptomatic bacteriuria. It is important to appropriately screen and treat asymptomatic bacteriuria only when there is evidence of potential benefit.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4应助提拉米苏采纳,获得10
刚刚
沧海一声笑完成签到,获得积分10
刚刚
科研通AI6.4应助fairy采纳,获得30
刚刚
顾矜应助称心沁采纳,获得10
1秒前
QLLW应助温暖幻灵采纳,获得10
2秒前
2秒前
2秒前
kofuns发布了新的文献求助10
3秒前
余歌发布了新的文献求助10
5秒前
bkagyin应助無羁采纳,获得10
5秒前
深情安青应助staxery采纳,获得30
6秒前
HH发布了新的文献求助10
7秒前
搜集达人应助草莓采纳,获得10
7秒前
7秒前
共享精神应助机灵猕猴桃采纳,获得10
8秒前
黄色垃圾桶住户完成签到,获得积分10
9秒前
大模型应助rainbow采纳,获得10
10秒前
深情安青应助王潇东采纳,获得10
12秒前
完美的香芦完成签到,获得积分10
12秒前
量子星尘发布了新的文献求助10
13秒前
温暖幻灵完成签到,获得积分10
13秒前
15秒前
17秒前
冷静完成签到,获得积分10
19秒前
祝君早日毕业完成签到,获得积分10
19秒前
加油小白菜完成签到,获得积分10
19秒前
Blx完成签到,获得积分10
21秒前
winwin发布了新的文献求助10
21秒前
21秒前
sibo完成签到,获得积分10
23秒前
24秒前
hey完成签到,获得积分0
25秒前
脑洞疼应助hbhbj采纳,获得10
25秒前
YifanWang应助may采纳,获得10
25秒前
25秒前
天棱发布了新的文献求助10
26秒前
LaTeXer应助sa0022采纳,获得200
27秒前
27秒前
自觉水绿发布了新的文献求助10
28秒前
QQQ完成签到,获得积分10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Polymorphism and polytypism in crystals 1000
Relation between chemical structure and local anesthetic action: tertiary alkylamine derivatives of diphenylhydantoin 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Der Gleislage auf der Spur 500
Principles of town planning : translating concepts to applications 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6075913
求助须知:如何正确求助?哪些是违规求助? 7907032
关于积分的说明 16350372
捐赠科研通 5214101
什么是DOI,文献DOI怎么找? 2788226
邀请新用户注册赠送积分活动 1771008
关于科研通互助平台的介绍 1648442